Multiple sclerosis: Repurposing dopaminergic drugs for MS — the evidence mounts

@article{Marino2016MultipleSR,
  title={Multiple sclerosis: Repurposing dopaminergic drugs for MS — the evidence mounts},
  author={F. Marino and M. Cosentino},
  journal={Nature Reviews Neurology},
  year={2016},
  volume={12},
  pages={191-192}
}
A new study has shown that both in patients with multiple sclerosis (MS) and in healthy controls, dopamine inhibits production of IL-17 and IFN-γ by peripheral blood mononuclear cells. The finding adds to previous evidence for the potential benefit of dopaminergic drugs in MS. 
21 Citations
Dopaminergic Therapeutics in Multiple Sclerosis: Focus on Th17-Cell Functions
  • 7
Dopamine, T cells and multiple sclerosis (MS)
  • 22
Immunomodulatory Effects Mediated by Dopamine
  • 55
  • PDF
Dopaminergic Regulation of Innate Immunity: a Review
  • 60
...
1
2
3
...

References

SHOWING 1-10 OF 11 REFERENCES
Immunopathogenesis and immunotherapy of multiple sclerosis
  • 242
Disturbed regulatory T cell homeostasis in multiple sclerosis.
  • 126
The Dopaminergic System in Autoimmune Diseases
  • 93
  • PDF
The immunoregulatory role of dopamine: An update
  • 208
The Physiology, Signaling, and Pharmacology of Dopamine Receptors
  • 1,783
  • PDF
...
1
2
...